Regeneron CEO on deal with Trump admin to lower drug prices

Regeneron inked a deal with the Trump administration to lower drug prices and avoid planned tariffs.

CEO Leonard Schleifer told CNBC’s “Squawk Box” on Friday that “we have to support this industry,” but “do it in a way that makes our drugs affordable.”